4-(3,4-二氯苯氧基)丁酸乙酯 | 91495-17-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 4-(3,4-二氯苯氧基)丁酸乙酯
• 英文名称: ethyl 4-(3,4-dichlorophenoxy)butanoate
• CAS: 91495-17-9
• 化学式: C₁₂H₁₄Cl₂O₃
• 分子量: 277.147
• InChiKey: OXDBJQHKIXUOBC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  17
• 可旋转键数：
  7
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  35.5
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-(3,4-二氯苯氧基)丁酸乙酯 在 盐酸羟胺 、 sodium methylate 作用下， 以 甲醇 为溶剂， 生成 (3,4-Dichlor-phenoxy)-butyrhydroxamsaeure
  参考文献：
  名称：

  Czerwinska,E. et al., Bulletin de l'Academie Polonaise des Sciences, Serie des Sciences Chimiques, 1961, vol. 9, p. 525 - 529

  摘要：

  DOI：
• 作为产物：
  描述：

  4-溴丁酸乙酯 、 3,4-二氯苯酚 在 potassium carbonate 作用下， 以 乙腈 为溶剂， 反应 24.0h， 生成 4-(3,4-二氯苯氧基)丁酸乙酯
  参考文献：
  名称：

  氯取代基和接头拓扑结构是5-HT6R活性的因子，对体内具有认知功能的新型高活性1,3,5-三嗪衍生物具有重要意义。

  摘要：

  根据最近的证据，5-HT 6 R配体是未来治疗记忆障碍的有前途的工具。因此，本研究提供了具有认知作用的强效5-HT 6 R药物，它代表了1,3,5-三嗪的原始化学类别，与广泛研究的砜和吲哚样5-HT 6 R配体不同。新化合物经过合理设计，是对铅4-（1-（2-氯苯氧基）乙基）-6-（4-甲基哌嗪-1-基）-1,3,5-三嗪-2-胺的修饰（1） ，涉及引入：（i）苯环上的两个氯和（ii）将三嗪环连接到芳族醚上的各种连接基。合成，体外和对19种新化合物进行了体内生物学测试和计算机辅助SAR分析。相对于5-HT 2A R，5-HT 7 R和D 2 R，大多数新的三嗪类 化合物对5-HT 6 R表现出高亲和力（K i <100 nM）和选择性。晶体学支持的对接研究包括量子极化的配体对接（QPLD），表明氯原子可能参与不同类型的卤素键，但是，连接子的性质似乎主要影响5-HT 6 R的亲和力。4- [1-（2

  DOI：

  10.1016/j.ejmech.2020.112529

文献信息

• [EN] CHEMICAL COMPOUNDS AS ATF4 PATHWAY INHIBITORS<br/>[FR] COMPOSÉS CHIMIQUES UTILISÉS COMME INHIBITEURS DE LA VOIE ATF4
  申请人：GLAXOSMITHKLINE IP DEV LTD

  公开号：WO2017212425A1

  公开（公告）日：2017-12-14

  The invention is directed to substituted piperidine derivatives. Specifically, the invention is directed to compounds according to Formula IIII: wherein A, B, X, Y, L1, L2, L3, R1, R2, R3, R4, R5, R6, R9, z2, z4, z5, and z6 are as defined herein, and salts thereof. The compounds of the invention are inhibitors of the ATF4 pathway and can be useful in the treatment of cancer, pre-cancerous syndromes and diseases associated with activated unfolded protein response pathways, such as Alzheimer's disease, spinal cord injury, traumatic brain injury, ischemic stroke, stroke, diabetes, Parkinson disease, Huntington's disease, Creutzfeldt-Jakob Disease, and related prion diseases, progressive supranuclear palsy, amyotrophic lateral sclerosis, myocardial infarction, cardiovascular disease, inflammation, fibrosis, chronic and acute diseases of the liver, chronic and acute diseases of the lung, chronic and acute diseases of the kidney, chronic traumatic encephalopathy (CTE), neurodegeneration, dementia, cognitive impairment, atherosclerosis, ocular diseases, arrhythmias, in organ transplantation and in the transportation of organs for transplantation. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting the ATF4 pathway and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

  该发明涉及替代哌啶衍生物。具体而言，该发明涉及符合以下式III的化合物：其中A、B、X、Y、L1、L2、L3、R1、R2、R3、R4、R5、R6、R9、z2、z4、z5和z6如本文所定义，并其盐。该发明的化合物是ATF4途径的抑制剂，可用于治疗癌症、癌前综合征以及与激活的未折叠蛋白应答途径相关的疾病，如阿尔茨海默病、脊髓损伤、创伤性脑损伤、缺血性中风、中风、糖尿病、帕金森病、亨廷顿病、克雅氏病及相关朊蛋白病、进行性核上性麻痹、肌萎缩侧索硬化、心肌梗死、心血管疾病、炎症、纤维化、肝脏慢性和急性疾病、肺部慢性和急性疾病、肾脏慢性和急性疾病、慢性创伤性脑病（CTE）、神经退行性疾病、痴呆、认知障碍、动脉粥样硬化、眼部疾病、心律失常、器官移植以及器官移植运输。因此，该发明进一步涉及包含该发明化合物的药物组合物。该发明还进一步涉及使用该发明化合物或包含该发明化合物的药物组合物抑制ATF4途径和治疗相关疾病的方法。
• [EN] QUATERNARY SALT CCR2 ANTAGONISTS<br/>[FR] ANTAGONISTES DE CCR2 A BASE DE SELS QUATERNAIRES
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2006012135A1

  公开（公告）日：2006-02-02

  Quaternary salt compounds of Formula (I) or pharmaceutically acceptable forms thereof, which are CCR2 antagonists and are useful in preventing, treating or ameliorating CCR2 mediated inflammatory syndromes, disorders or diseases in a subject in need thereof.

  Formula (I)的四价盐化合物或其药学上可接受的形式，其为CCR2拮抗剂，可用于预防、治疗或改善CCR2介导的炎症综合征、疾病或症状。
• Quaternary salt CCR2 antagonists
  申请人：Lagu Bharat

  公开号：US20060293379A1

  公开（公告）日：2006-12-28

  Quaternary salt compounds of Formula (I) or pharmaceutically acceptable forms thereof, which are CCR2 antagonists and are useful in preventing, treating or ameliorating CCR2 mediated inflammatory syndromes, disorders or diseases in a subject in need thereof.

  Formula（I）的四价盐化合物或其药用可接受形式，是CCR2拮抗剂，可用于预防、治疗或改善需要的受体中介的炎症综合征、紊乱或疾病。
• Chlorine substituents and linker topology as factors of 5-HT6R activity for novel highly active 1,3,5-triazine derivatives with procognitive properties in vivo
  作者：Sylwia Sudoł、Katarzyna Kucwaj-Brysz、Rafał Kurczab、Natalia Wilczyńska、Magdalena Jastrzębska-Więsek、Grzegorz Satała、Gniewomir Latacz、Monika Głuch-Lutwin、Barbara Mordyl、Ewa Żesławska、Wojciech Nitek、Anna Partyka、Kamila Buzun、Agata Doroz-Płonka、Anna Wesołowska、Anna Bielawska、Jadwiga Handzlik

  DOI：10.1016/j.ejmech.2020.112529

  日期：2020.10

  promising tool for future treatment of memory impairment. Hence, this study has supplied highly potent 5-HT6R agents with procognitive effects, which represent an original chemical class of 1,3,5-triazines, different from widely studied sulfone and indole-like 5-HT6R ligands. The new compounds were rationally designed as modifications of lead, 4-(1-(2-chlorophenoxy)ethyl)-6-(4-methylpiperazin-1-yl)-1,3,5-triazin-2-amine

  根据最近的证据，5-HT 6 R配体是未来治疗记忆障碍的有前途的工具。因此，本研究提供了具有认知作用的强效5-HT 6 R药物，它代表了1,3,5-三嗪的原始化学类别，与广泛研究的砜和吲哚样5-HT 6 R配体不同。新化合物经过合理设计，是对铅4-（1-（2-氯苯氧基）乙基）-6-（4-甲基哌嗪-1-基）-1,3,5-三嗪-2-胺的修饰（1） ，涉及引入：（i）苯环上的两个氯和（ii）将三嗪环连接到芳族醚上的各种连接基。合成，体外和对19种新化合物进行了体内生物学测试和计算机辅助SAR分析。相对于5-HT 2A R，5-HT 7 R和D 2 R，大多数新的三嗪类 化合物对5-HT 6 R表现出高亲和力（K i <100 nM）和选择性。晶体学支持的对接研究包括量子极化的配体对接（QPLD），表明氯原子可能参与不同类型的卤素键，但是，连接子的性质似乎主要影响5-HT 6 R的亲和力。4- [1-（2
• Identification of 5-Substituted 2-Acylaminothiazoles That Activate Tat-Mediated Transcription in HIV-1 Latency Models
  作者：William Nguyen、Jonathan Jacobson、Kate E. Jarman、Helene Jousset Sabroux、Leigh Harty、James McMahon、Sharon R. Lewin、Damian F. Purcell、Brad E. Sleebs

  DOI：10.1021/acs.jmedchem.9b00462

  日期：2019.5.23

  The persistent reservoir of cells latently infected with human immunodeficiency virus (HIV)-integrated proviral DNA necessitates lifelong suppressive antiretroviral therapy (ART). Epigenetic targeted compounds have shown promise as potential latency-reversing agents; however, these drugs have undesirable toxicity and lack specificity for HIV. We utilized a novel HEK293-derived FlpIn dual-reporter cell line, which quantifies specific HIV provirus reactivation (LTR promoter) relative to nonspecific host cell gene expression (CMV promoter), to identify the 5-substituted 2-acylaminothiazole hit class. Here, we describe the optimization of the hit class, defining the functionality necessary for HIV gene activation and for improving in vitro metabolism and solubility. The optimized compounds displayed enhanced HIV gene expression in HEK293 and Jurkat 10.6 latency cellular models and increased unspliced HIV RNA in resting CD4+ T cells isolated from HIV-infected individuals on ART, demonstrating the potential of the 2-acylaminothiazole class as latency-reversing agents.